about
Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rateAspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.New approaches to preventing restenosis.Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients.Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2.Analysis of prosthetic cardiac devices: a guide for the practising pathologist.Decision models for assessing the cost effectiveness of drug-eluting stents.Drug-eluting stents: from evidence to policy.Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices?BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis modelClinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India.Issues in the acquisition, development, and use of technology in health care.Crush stenting with paclitaxel-eluting or sirolimus-eluting stents for the treatment of coronary bifurcation lesions.Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.Intracoronary beta-irradiation enhances balloon-injury-induced tissue factor expression in the porcine injury model.Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study.Plaque sealing--a concept waiting for support.Dollars and stents: the economics of drug-eluting stents.Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rate.Propensity score models in observational comparative effectiveness studies: cornerstone of design or statistical afterthought?
P2860
Q25257554-6A204314-BC85-4420-8006-EB501632FCF4Q34771381-8982CA82-3F5C-429F-A118-7440BF77B707Q35190937-56100B30-0C3F-423B-9151-1B62522E0CC4Q35591181-B78E9182-A7DF-484B-9A63-C6A5A95E0F50Q35708574-C5F6B6D2-DA22-45F9-ABD8-226C94EB95A2Q36022746-4454E746-C5F5-4FD0-AF2D-F5E9B1312ACFQ36161276-B53E4C43-8879-4E47-80C8-EDAF0E76AED2Q36314909-19778CA2-03BD-4C95-862A-6625E1C34D70Q36412659-91340C94-0DF8-4929-9751-5573FDF96BA5Q36728852-B3835866-D999-4F8F-B006-8DD19D8DA321Q37221177-378F9E1B-6D0E-4A66-ACC7-C2F176758243Q37388164-D44FEB87-7C8E-42C1-BD37-F84CC6224C27Q42562246-4CCCBF5B-D7C1-436F-A0A7-A298CFB4F5C6Q44946760-5DB76F3C-0249-4DB4-B6E2-464865AC29B9Q45152233-55F7D309-13E2-4E6E-AF47-C9EA9C7622BAQ45287552-1394957E-86DD-4AE7-BD72-7D569609D65BQ46042292-821D7654-24E2-4FF7-B230-F888EDD34594Q47623826-754772C4-4F16-4A04-9128-5164C5E03ADFQ51373459-D492F468-68FF-4F78-847E-C751DFF54788Q51484880-8BF91BDB-D32C-4EBA-9785-7CB26ABB6ABBQ53767304-12AF10B7-6E60-449F-AC6A-C5FF2196A98FQ57644099-8847856E-5193-454B-8B32-7DFD4A888C40
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Drug-eluting stents: costs versus clinical benefit.
@ast
Drug-eluting stents: costs versus clinical benefit.
@en
type
label
Drug-eluting stents: costs versus clinical benefit.
@ast
Drug-eluting stents: costs versus clinical benefit.
@en
prefLabel
Drug-eluting stents: costs versus clinical benefit.
@ast
Drug-eluting stents: costs versus clinical benefit.
@en
P1433
P1476
Drug-eluting stents: costs versus clinical benefit.
@en
P2093
Martin B Leon
William W O'Neill
P304
P356
10.1161/01.CIR.0000079018.84618.0E
P407
P577
2003-06-01T00:00:00Z